Showing 1971-1980 of 2314 results for "".
- Allegro Announces Positive Results of Vehicle-Controlled Ex-US Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/allegro-announces-positive-results-of-vehicle-controlled-ex-us-phase-2-trial-of-alg-1007-for-the-treatment-of-dry-eye-disease/2479410/Allegro Ophthalmics announced that all primary and secondary endpoints of an ex-US vehicle-controlled study of ALG-1007 topical eye drop in patients with dry eye disease (DED) were met. The results were presented by Eric D. Donnenfeld, MD, at the 2021 American Society of Cataract and Refractive S
- Modernizing Medicine Showcases Single-Screen Innovations at ASCRShttps://modernod.com/news/modernizing-medicine-showcases-single-screen-innovations-at-ascrs/2479405/Modernizing Medicine announced it has enhanced its electronic health records (EHR), EMA with functionality that can help to speed up documentation by removing steps in note-taking and allowing for quick editing, importing charts and more. These new and improved workflows for clinical docu
- First Eye Care-Focused SPAC, LifeLong Vision, Launchedhttps://modernod.com/news/first-eye-care-focused-spac-lifelong-vision-to-host-launch-event/2479368/A new multi-billion dollar initiative that aims to provide daily access to eye care through any mobile device officially launched on Wednesday. LifeLong Vision, which is backed by investment banking platform MedHealth Capital, is set to emerge via a Special Purpose Acquisition Company (SPA
- Pfizer Plans to Seek FDA Nod for COVID-19 Booster Next Month as Delta Spreadshttps://modernod.com/news/pfizer-plans-to-seek-fda-nod-for-covid-19-booster-next-month-as-delta-spreads/2479354/Pfizer’s chief scientific officer Mikael Dolsten indicated Thursday that the company plans to seek an FDA emergency-use authorization next month for a third dose of its COVID-19 vaccine BNT162b2, according to a FirstWord report. The mRNA-based vaccine, partnered with BioNTech, is cur
- EyePoint Pharmaceuticals Reports Positive 30-Day Safety Results for All Cohorts From DAVIO Trial of EYP-1901 for Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-reports-positive-30-day-safety-results-for-all-cohorts-from-the-davio-trial-of-eyp-1901-for-wet-amd/2479344/EyePoint Pharmaceuticals announced positive safety results from its phase 1 clinical trial of EYP-1901, a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (AMD). All dose cohorts have reached at least 30-day post-dosing foll
- Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpointshttps://modernod.com/news/ocuphires-vega-1-phase-2-trial-in-presbyopia-meets-primary-and-secondary-endpoints/2479332/Ocuphire Pharma announced that the VEGA-1 phase 2 clinical trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine (LDP) in presbyopic subjects successfully met its primary and many secondary endpoints. On the strength of these results, Ocuphire plans to move in
- Gemini Therapeutics Announces Data From Ongoing Phase 2a Study in Patients with GA Secondary to Dry AMDhttps://modernod.com/news/gemini-therapeutics-announces-initial-data-from-its-ongoing-phase-2a-study-of-gem103-in-patients-with-geographic-atrophy-secondary-to-dry-amd/2479317/Gemini Therapeutics announced initial data from its phase 2a ReGAtta study of GEM103 as of May 2021 in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). ReGAtta is a dose escalation trial of GEM103, which is intravitreally administered recombinant huma
- Glaukos Completes Patient Enrollment in US NDA Phase 3 Clinical Trials for iDose TRhttps://modernod.com/news/glaukos-completes-patient-enrollment-in-us-nda-phase-3-clinical-trials-for-idose-tr/2479280/Glaukos announced the completion of patient enrollment and randomization in its FDA new drug application (NDA) phase 3 clinical trials for the iDose TR sustained-release travoprost implant. The iDose TR phase 3 clinical program consists of two prospective, randomized, double-
- Oxurion Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of DMEhttps://modernod.com/news/oxurion-completes-patient-enrollment-for-part-a-of-phase-2-study-evaluating-thr-149-for-treatment-of-dme/2479273/Oxurion NV announced the completion of patient enrollment into Part A of its two part phase 2 study (KALAHARI) evaluating multiple injections of THR-149 for the treatment of DME. Dose selection data from Part A of the study is expected in the second half of 2021. THR-149, Oxurion’s most ad
- Scientists Use Video Games to Shed Light on the Link Between Motor Activity and Visionhttps://modernod.com/news/scientists-use-video-games-to-shed-light-on-the-link-between-motor-activity-and-vision/2479266/It’s a well established fact—and intuitive truth—that vision guides movement, and that information flows readily from the visual cortex to motor centers. However, the inverse relation is far less well understood. Does engaging in movement affect how our vision is processed? Three researchers from